vs
Side-by-side financial comparison of Li Bang International Corp Inc. (LBGJ) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $4.7M, roughly 1.4× Li Bang International Corp Inc.). Li Bang International Corp Inc. runs the higher net margin — -23.9% vs -303.5%, a 279.6% gap on every dollar of revenue.
Li & Fung Limited is a Hong Kong–based supply chain management company. Established in 1906, the company became publicly traded in 1973 and has since played a significant role in manufacturing apparel, toys, and various consumer goods for major North American and European retailers. Significant growth occurred after its public listing, reaching a peak market capitalization in 2011, but the rise of platforms like Alibaba and Amazon, which directly connect manufacturers with consumers, created ...
LBGJ vs PRLD — Head-to-Head
Income Statement — Q4 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.7M | $6.5M |
| Net Profit | $-1.1M | $-19.7M |
| Gross Margin | 17.8% | — |
| Operating Margin | -25.1% | -314.1% |
| Net Margin | -23.9% | -303.5% |
| Revenue YoY | — | 116.7% |
| Net Profit YoY | — | 38.9% |
| EPS (diluted) | $-0.06 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $6.5M | ||
| Q4 24 | $4.7M | — | ||
| Q3 24 | — | $3.0M |
| Q3 25 | — | $-19.7M | ||
| Q4 24 | $-1.1M | — | ||
| Q3 24 | — | $-32.3M |
| Q3 25 | — | — | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | — | — |
| Q3 25 | — | -314.1% | ||
| Q4 24 | -25.1% | — | ||
| Q3 24 | — | -1145.9% |
| Q3 25 | — | -303.5% | ||
| Q4 24 | -23.9% | — | ||
| Q3 24 | — | -1075.7% |
| Q3 25 | — | $-0.26 | ||
| Q4 24 | $-0.06 | — | ||
| Q3 24 | — | $-0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $55.0M |
| Total DebtLower is stronger | $10.2M | — |
| Stockholders' EquityBook value | $7.8M | $58.5M |
| Total Assets | $28.8M | $94.8M |
| Debt / EquityLower = less leverage | 1.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $55.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $153.6M |
| Q3 25 | — | — | ||
| Q4 24 | $10.2M | — | ||
| Q3 24 | — | — |
| Q3 25 | — | $58.5M | ||
| Q4 24 | $7.8M | — | ||
| Q3 24 | — | $156.4M |
| Q3 25 | — | $94.8M | ||
| Q4 24 | $28.8M | — | ||
| Q3 24 | — | $197.2M |
| Q3 25 | — | — | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $258.4K | $-19.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-19.1M | ||
| Q4 24 | $258.4K | — | ||
| Q3 24 | — | $-27.3M |
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-27.4M |
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -912.0% |
| Q3 25 | — | 0.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
